Moreover, Mogamulizumab, an anti-CCR4 monoclonal antibody, effectively eliminates Tregs through ADCC in adult T-cell leukemia-lymphoma patients, significantly increasing tumor-specific CD8+ T cells and promoting secretion of IFN-γ and TNF-α. Here, CD8A is linked to neoplasm.